Edition:
United Kingdom

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

24.95USD
23 Feb 2018
Change (% chg)

$-0.45 (-1.77%)
Prev Close
$25.40
Open
$25.65
Day's High
$26.80
Day's Low
$24.70
Volume
782,116
Avg. Vol
393,880
52-wk High
$27.50
52-wk Low
$3.65

Select another date:

Thu, Feb 22 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead

* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer

* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant

* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV

Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

Sangamo partners with Pfizer to develop gene therapy for ALS

Jan 3 Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

Select another date: